TSW
ANIP icon

Thompson Siegel & Walmsley’s ANI Pharmaceuticals ANIP Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.67M Sell
92,691
-20,312
-18% -$1.63M 0.14% 177
2026
Q1 		$8.69M Buy
113,003
+12,944
+13% +$1.01M 0.15% 148
2025
Q4 		$7.9M Buy
100,059
+8,626
+9% +$747K 0.13% 158
2025
Q3 		$8.38M Sell
91,433
-152,987
-63% -$12.5M 0.14% 152
2025
Q2 		$15.9M Buy
244,420
+7,393
+3% +$481K 0.27% 95
2025
Q1 		$15.9M Sell
237,027
-46,833
-16% -$2.8M 0.27% 94
2024
Q4 		$15.7M Buy
283,860
+53,701
+23% +$3.08M 0.24% 101
2024
Q3 		$13.7M Buy
230,159
+34,416
+18% +$2.1M 0.2% 110
2024
Q2 		$12.5M Buy
195,743
+2,986
+2% +$194K 0.2% 111
2024
Q1 		$13.3M Sell
192,757
-20,154
-9% -$1.22M 0.2% 109
2023
Q4 		$11.7M Sell
212,911
-15,796
-7% -$870K 0.19% 116
2023
Q3 		$13.3M Sell
228,707
-133,584
-37% -$7.71M 0.22% 101
2023
Q2 		$19.5M Sell
362,291
-31,498
-8% -$1.4M 0.31% 87
2023
Q1 		$15.6M Sell
393,789
-21,491
-5% -$906K 0.25% 96
2022
Q4 		$16.7M Sell
415,280
-682
-0.2% -$25.6K 0.27% 97
2022
Q3 		$13.4M Sell
415,962
-19,911
-5% -$682K 0.23% 109
2022
Q2 		$12.9M Buy
435,873
+11,786
+3% +$340K 0.21% 114
2022
Q1 		$11.9M Buy
424,087
+144,533
+52% +$5.39M 0.17% 134
2021
Q4 		$12.9M Sell
279,554
-170,950
-38% -$7.35M 0.18% 136
2021
Q3 		$14.8M Buy
450,504
+70,030
+18% +$2.18M 0.21% 115
2021
Q2 		$13.3M Buy
380,474
+51,935
+16% +$1.77M 0.18% 120
2021
Q1 		$11.9M Sell
328,539
-4,268
-1% -$134K 0.17% 127
2020
Q4 		$9.66M Sell
332,807
-4,231
-1% -$121K 0.15% 133
2020
Q3 		$9.51M Buy
337,038
+38,104
+13% +$1.13M 0.18% 119
2020
Q2 		$9.67M Buy
298,934
+294,992
+7,483% +$10.6M 0.19% 114
2020
Q1 		$161K Buy
+3,942
New +$210K ﹤0.01% 329

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thompson Siegel & Walmsley's ANIP Position: Q2 2026 in Review

Thompson Siegel & Walmsley reduced its ANI Pharmaceuticals (ANIP) stake by 18% in Q2 2026, selling an estimated $1.63M and leaving 92,691 shares worth $7.67M. The position accounts for 0.14% of the portfolio, ranked #177.

Thompson Siegel & Walmsley first reported a position in ANIP in Q1 2020 and has held it in 26 quarters since. The position peaked at $19.5M in Q2 2023. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Thompson Siegel & Walmsley held 92,691 shares of ANI Pharmaceuticals worth $7.67M as of Q2 2026.
  • Thompson Siegel & Walmsley sold 20,312 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.63M.
  • ANI Pharmaceuticals made up 0.14% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #177 holding.
  • Thompson Siegel & Walmsley first reported a position in ANI Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Thompson Siegel & Walmsley's ANI Pharmaceuticals position peaked at $19.5M in Q2 2023.
  • 308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.